According to Biohaven, the FDA’s decision on the NDA is expected during the 3rd quarter of 2025. The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application ...

Respiratory tract diseases are illnesses that affect components of the respiratory system, including the nasal passages, the bronchi and the lungs. They range from acute infections, such as ...